The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease. The genetic alterations underlying this heterogeneity have been thoroughly characterized through omic approaches requiring elevated efforts and costs. In order to translate the knowledge of CRC molecular heterogeneity into a practical clinical approach, we utilized a simplified Next Generation Sequencing (NGS) based platform to screen a cohort of 77 patients treated with first-line conventional therapy. Samples were sequenced using a panel of hotspots and targeted regions of 22 genes commonly involved in CRC. This revealed 51 patients carrying actionable gene mutations, 22 of which carried druggable alterations. These mutations were frequently associated with additional genetic alterations. To take into account this molecular complexity and assisted by an unbiased bioinformatic analysis, we defined three subgroups of patients carrying distinct molecular patterns. We demonstrated these three molecular subgroups are associated with a different response to first-line conventional combination therapies. The best outcome was achieved in patients exclusively carrying mutations on TP53 and/or RAS genes. By contrast, in patients carrying mutations in any of the other genes, alone or associated with mutations of TP53/RAS, the expected response is much worse compared to patients with exclusive TP53/RAS mutations. Additionally, our data indicate that the standard approach has limited efficacy in patients without any mutations in the genes included in the panel. In conclusion, we identified a reliable and easy-to-use approach for a simplified molecular-based stratification of mCRC patients that predicts the efficacy of the first-line conventional combination therapy.

A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer / Capalbo, Carlo; Belardinilli, Francesca; Raimondo, Domenico; Milanetti, Edoardo; Malapelle, Umberto; Pisapia, Pasquale; Magri, Valentina; Prete, Alessandra; Pecorari, Silvia; Colella, Mariarosaria; Coppa, Anna; Bonfiglio, Caterina; Nicolussi, Arianna; Valentini, Virginia; Tessitore, Alessandra; Cardinali, Beatrice; Petroni, Marialaura; Infante, Paola; Santoni, Matteo; Filetti, Marco; Colicchia, Valeria; Paci, Paola; Mezi, Silvia; Longo, Flavia; Cortesi, Enrico; Marchetti, Paolo; Troncone, Giancarlo; Bellavia, Diana; Canettieri, Gianluca; Giannini, Giuseppe. - In: CANCERS. - ISSN 2072-6694. - 11:2(2019). [10.3390/cancers11020147]

A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer

Capalbo, Carlo
Primo
;
Belardinilli, Francesca
Secondo
;
Raimondo, Domenico;Milanetti, Edoardo;Magri, Valentina;Prete, Alessandra;Pecorari, Silvia;Coppa, Anna;Nicolussi, Arianna;Valentini, Virginia;Cardinali, Beatrice;Petroni, Marialaura;Infante, Paola;Filetti, Marco;Colicchia, Valeria;Paci, Paola;Mezi, Silvia;Cortesi, Enrico;Marchetti, Paolo;Bellavia, Diana;Canettieri, Gianluca
Penultimo
;
Giannini, Giuseppe
Ultimo
2019

Abstract

The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease. The genetic alterations underlying this heterogeneity have been thoroughly characterized through omic approaches requiring elevated efforts and costs. In order to translate the knowledge of CRC molecular heterogeneity into a practical clinical approach, we utilized a simplified Next Generation Sequencing (NGS) based platform to screen a cohort of 77 patients treated with first-line conventional therapy. Samples were sequenced using a panel of hotspots and targeted regions of 22 genes commonly involved in CRC. This revealed 51 patients carrying actionable gene mutations, 22 of which carried druggable alterations. These mutations were frequently associated with additional genetic alterations. To take into account this molecular complexity and assisted by an unbiased bioinformatic analysis, we defined three subgroups of patients carrying distinct molecular patterns. We demonstrated these three molecular subgroups are associated with a different response to first-line conventional combination therapies. The best outcome was achieved in patients exclusively carrying mutations on TP53 and/or RAS genes. By contrast, in patients carrying mutations in any of the other genes, alone or associated with mutations of TP53/RAS, the expected response is much worse compared to patients with exclusive TP53/RAS mutations. Additionally, our data indicate that the standard approach has limited efficacy in patients without any mutations in the genes included in the panel. In conclusion, we identified a reliable and easy-to-use approach for a simplified molecular-based stratification of mCRC patients that predicts the efficacy of the first-line conventional combination therapy.
NGS; chemotherapy; genomic profiling; precision medicine; predictive
01 Pubblicazione su rivista::01a Articolo in rivista
A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer / Capalbo, Carlo; Belardinilli, Francesca; Raimondo, Domenico; Milanetti, Edoardo; Malapelle, Umberto; Pisapia, Pasquale; Magri, Valentina; Prete, Alessandra; Pecorari, Silvia; Colella, Mariarosaria; Coppa, Anna; Bonfiglio, Caterina; Nicolussi, Arianna; Valentini, Virginia; Tessitore, Alessandra; Cardinali, Beatrice; Petroni, Marialaura; Infante, Paola; Santoni, Matteo; Filetti, Marco; Colicchia, Valeria; Paci, Paola; Mezi, Silvia; Longo, Flavia; Cortesi, Enrico; Marchetti, Paolo; Troncone, Giancarlo; Bellavia, Diana; Canettieri, Gianluca; Giannini, Giuseppe. - In: CANCERS. - ISSN 2072-6694. - 11:2(2019). [10.3390/cancers11020147]
File allegati a questo prodotto
File Dimensione Formato  
Capalbo_A Simplified Genomic_2019.pdf

accesso aperto

Note: https://www.mdpi.com/2072-6694/11/2/147
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1224164
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact